What is the market price of molotinib/mometinib as a targeted anti-tumor drug?

Momelotinib is a targeted anti-tumor drug, mainly used for the treatment of myelofibrosis (MF). Although it has been approved and launched in overseas markets, it has not been officially launched in China, so it currently cannot enjoy medical insurance benefits. This means that Chinese patients need to bear higher costs when using the drug.

In overseas markets, especially in the United States, the original drug of molotinib is usually sold in dosage specifications of 100mg, 150mg and 200mg, with each box containing 30 tablets. According to market data, the price of these specifications is approximately 200,000 yuan, and the specific price may be affected by exchange rate fluctuations. This price is quite expensive for many patients, especially if long-term treatment is required, and the financial burden can be imagined.

It is worth mentioning that as the demand for molotinib increases, the first generic drug has also been released. For example, the 100 mg molotinib generic drug launched by Lucius Pharmaceuticals in Laos is priced at just over 2,000 yuan, which is significantly lower than the price of the original drug. This makes this treatment option more affordable for more patients, resulting in better outcomes. Although the ingredients of generic drugs are basically the same as those of the original drugs, they also need to meet certain safety and effectiveness standards during pre-market clinical trials and regulatory reviews to ensure that they can be used safely.

Since the market price of molotinib is generally high, some patients and their families have to consider financial factors when facing treatment options. Abroad, many patients may seek private insurance or other forms of Medicaid to alleviate the financial stress of drug costs. For more information on overseas drug prices and related information, please consult Yaode Medical Consultants.

Reference materials:https://en.wikipedia.org/wiki/Momelotinib